Table of Contents Author Guidelines Submit a Manuscript
International Journal of Breast Cancer
Volume 2012, Article ID 385978, 7 pages
http://dx.doi.org/10.1155/2012/385978
Review Article

Triple-Negative Breast Cancer: An Update on Neoadjuvant Clinical Trials

1Division of Surgical Oncology, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA
2Lineberger Comprehensive Cancer Center, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA
3Department of Human Pathology, Integrated Therapies in Oncology Unit, University of Messina, 98125 Messina, Italy
4Division of Hematology/Oncology, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA

Received 18 July 2011; Revised 13 October 2011; Accepted 13 October 2011

Academic Editor: Quyen D. Chu

Copyright © 2012 Keith D. Amos et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Triple-negative breast cancer (TNBC) is an aggressive malignancy with a poor prognosis despite the high rates of response to chemotherapy. This scenario highlights the need to develop novel therapies and/or treatment strategies to reduce the mortality associated with TNBC. The neoadjuvant setting provides a model for rapid assessment of treatment efficacy with smaller patient accruals and over shorter periods of time compared to the traditional adjuvant setting. In addition, a clear surrogate endpoint of improved survival, known as pathologic complete response, already exists in this setting. Here, we review current data from completed and ongoing neoadjuvant clinical trials for TNBC.